NIH Reporter #11470595

LANCET-HBV: Hepatitis B Infection in the Era of Long-Acting ART

This NIH-funded project by University of California Los Angeles studies Hepatitis B infection during long-acting ART for HIV, aiming to improve management and clinical guidelines.

Description

The project focuses on Hepatitis B infection in the context of long-acting antiretroviral therapy (LA-ART) for HIV. It involves clinical, virologic, behavioral, and cost-effectiveness studies. The project is funded by the NIH, specifically the National Institute of Allergy and Infectious Diseases (NIAID). The project aims to define the incidence, predictors, and management strategies for HBV reactivation and infection during LA-ART. The project leverages the ACTG LANCET clinical trial (A5433). The project includes developing practical tools for real-world implementation and informing clinical guidelines.

View original record